Protalix (PLX) Q2 2026 Earnings Call Transcript

Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.

08/19/2026, 10:08 AM • The Motley Fool

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

The European Commission has approved a new every-4-weeks dosing regimen (2mg/kg) for Elfabrio® (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. This approval extends the infusion interval from every 2 weeks, reducing treatment burden for patients and healthcare systems. Protalix is entitled to a $25 million regulatory milestone payment from Chiesi. The FDA-approved dosing in the US remains unchanged at 1mg/kg every 2 weeks.

03/09/2026, 6:00 AM • GlobeNewswire